MyoGene Bio

MyoGene Bio is a biotechnology company headquartered in San Diego, California, developing a novel gene-editing therapy for Duchenne Muscular Dystrophy (DMD). MyoGene Bio's lead program is the gene-editing therapy, MyoDys45-55, for Duchenne Muscular Dystrophy (DMD), a devastating muscle-wasting disease. MyoGene Bio leverages new technology to have a powerful positive impact on disease progression by targeting the root cause of the disease.